In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.

Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

CAMBRIDGE, MA - Moderna , Inc. (NASDAQ:MRNA) has secured a tender to supply its mRNA COVID-19 vaccine to the European Union, including additional countries Norway and North Macedonia. The agreement, ...

COVID-19 vaccines used in Brazil are from three different technology platforms. Besides Pfizer's, which contains synthetic RNA from SARS-CoV-2 ... booster dose with an mRNA vaccine such as Moderna ...

Sales at the once-high-flying biotech will likely continue to shrink for a while. But Moderna has a new cash cow in development, along with other potential winners. The U.S. government should ...

In the fight against COVID-19, two FDA-approved mRNA vaccines were developed by Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), which produce the SARS-CoV-2 spike protein to activate ... and ...

Moderna has ... that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel. The phase 1/2 study involved 895 subjects ...

The company will also design up to four other novel pandemic flu vaccines and do the phase 1 clinical studies. Moderna says results from early trials are positive In a statement on the same day, ...

According to Pfizer and BioNTech, this is the first time that an mRNA-based flu vaccine has started a phase 3 efficacy trial. Its rival Moderna said ... jab in a phase 1/2 trial, while a triple ...

The hepatitis B vaccine offers effective protection against HBV for infants, children, adolescents, and adults. Infants should receive one dose of the vaccine just after birth, followed by a second ...